Kymera Therapeutics (KYMR) Non-Current Deffered Revenue (2019 - 2025)

Kymera Therapeutics (KYMR) has reported Non-Current Deffered Revenue for 7 consecutive years, with $11.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $11.4 million; the TTM figure through Dec 2025 stood at $11.4 million (changed N/A YoY), while the FY2025 annual figure was $11.4 million, changed N/A from the prior year.
• Non-Current Deffered Revenue retreated to $11.4 million in Q4 2025 per KYMR's latest filing, from $14.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $64.7 million in Q1 2021 and bottomed at $3.2 million in Q2 2024.
• Historically, Non-Current Deffered Revenue has averaged $27.6 million across 5 years, with a median of $23.9 million in 2022.
• On a YoY basis, Non-Current Deffered Revenue climbed as much as 4.36% in 2024 and fell as far as 84.38% in 2024.
• Kymera Therapeutics' Non-Current Deffered Revenue stood at $39.3 million in 2021, then fell by 28.74% to $28.0 million in 2022, then slumped by 40.11% to $16.8 million in 2023, then slumped by 80.98% to $3.2 million in 2024, then jumped by 258.73% to $11.4 million in 2025.
• Business Quant data shows KYMR's Non-Current Deffered Revenue at $11.4 million in Q4 2025, $14.0 million in Q3 2025, and $3.2 million in Q2 2024.